Determining Pharmacological Mechanisms of Chinese Incompatible Herbs Fuzi and Banxia in Chronic Obstructive Pulmonary Disease: A Systems Pharmacology-Based Study

الملخص EN

Aconiti Lateralis Radix Praeparata (Fuzi) and Pinelliae Rhizoma (Banxia) are among the 18 incompatible medications that are forbidden from use in one formulation.

However, there is increasing evidence implying that this prohibition is not entirely correct.

According to the theory of Chinese traditional medicine, they can be used for the treatment of chronic obstructive pulmonary disease (COPD).

Thus, we analyzed the possible approaches for the treatment of COPD using network pharmacology.

The active compounds of Fuzi and Banxia (FB) were collected, and their targets were identified.

COPD-related targets were obtained by analyzing the differentially expressed genes between COPD patients and healthy individuals, which were expressed using a Venn diagram of COPD and FB.

Protein-protein interaction data and network regarding COPD and drugs used were obtained.

Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis were conducted.

The gene-pathway network was constructed to screen the key target genes.

In total, 34 active compounds and 47 targets of FB were identified; moreover, 7,153 differentially expressed genes were identified between COPD patients and healthy individuals.

The functional annotations of target genes were found to be related to mechanisms such as transcription, cytosol, and protein binding; furthermore, 68 pathways including neuroactive ligand-receptor interaction, Kaposi sarcoma-associated herpesvirus infection, apoptosis, and measles were significantly enriched.

FOS CASP3, VEGFA, ESR1, and PTGS2 were the core genes in the gene-pathway network of FB for the treatment of COPD.

Our results indicated that the effect of FB against COPD may involve the regulation of immunological function through several specific biological processes and their corresponding pathways.

This study demonstrates the application of network pharmacology in evaluating mechanisms of action and molecular targets of herb-opponents FB.